Next Gen Diagnostics Selected to Partner with a UK Consortium To Conduct The First Trial Of Prospective Sequencing-Enabled Transmission Detection, At Addenbrooke’s Hospital, In Cambridge, UK.

PRESS RELEASE
Written By Casey-Drew Williams

Next Gen Diagnostics (NGD) will partner with a Consortium funded by the Wellcome Trust and the United Kingdom Department of Health and Social Care under a 4.4M£ Health Innovation Challenge Fund (HICF) grant, to do the first deployment of prospective sequencing of all MRSA samples as a means to detect transmission of infection and thereby prevent outbreaks.  Led by Professor Sharon Peacock of the London School of Hygiene and Tropical Medicine and Julian Parkhill of the Wellcome Sanger Institute, the project will be done with Addenbrooke’s Hospital in Cambridge, UK, in close partnership with the leadership of Addenbrooke’s microbiology laboratory and infection control teams.

Casey-Drew Williams
Previous

Next Gen Diagnostics Announces that Dr. Tony Cox, Director of Advanced Sequencing Pipeline Research at the Wellcome Sanger Institute, Has Joined its Scientific Advisory Board
Next

Next Gen Diagnostics Announces that Professor Sharon Peacock, of the London School of Hygiene and Tropical Medicine, Has Joined its Scientific Advisory Board